24
total announcements
539519.BO · 15 min delayed
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has announced a strategic expansion and acquisition of a 60% controlling stake in Meyonex Pharmaceuticals for ₹67.19 Crore. The company is expanding into high-margin verticals, including APIs, finished dosage forms, CDMO, and nutraceuticals.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has announced a strategic business expansion and proposed acquisition of a 60% controlling stake in Meyonex Pharmaceuticals Ltd for ₹67.19 Crore. The acquisition aims to expand into high-margin segments such as APIs, finished dosage forms, and contract manufacturing services.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has submitted a certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th September, 2026, confirming the dematerialization of securities and listing on stock exchanges.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd approved the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, subject to necessary approvals and completion of definitive agreements. The consideration for the proposed acquisition will be ₹67,19,09,760/- made entirely in cash mode. The Board also approved the issue price of ₹32/- per equity share and the funding requirements for making the proposed investment.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd's Board of Directors approved the proposed acquisition of up to 60% of Meyonex Pharmaceuticals Limited's equity share capital, subject to necessary approvals and execution of definitive agreements. The consideration for the proposed acquisition will be ₹67,19,09,760, to be made entirely in cash mode. The Board also approved the issue price of ₹32 per equity share and the funding requirements for making the proposed investment.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has announced the voting results of its 46th Annual General Meeting (AGM) held on September 30, 2026, through video conferencing. The meeting was conducted in compliance with the relevant provisions of the Companies Act, 2013, and the Listing Regulations issued by SEBI.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd held its 46th Annual General Meeting (AGM) on September 30, 2026, through video conferencing. The meeting was attended by 57 members, and the company offered remote e-voting facility to its members. The results of e-voting will be declared within two working days from the conclusion of the AGM.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has scheduled a board meeting on 07/10/2026 to consider the proposed acquisition of up to 60% of Meyonex Pharmaceuticals Limited and to discuss other business.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Roshan Dealmark Pvt Ltd.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has closed its trading window for directors, promoters, and designated persons from October 1st, 2026, until 48 hours after the announcement of its un-audited financial results for the quarter ended September 30th, 2026.
Tavexia Lifecare Ltd
The BSE has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Roshan Dealmark Pvt Ltd regarding Tavexia Lifecare Ltd.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Roshan Dealmark Pvt Ltd & PAC, indicating a potential change in shareholding.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Roshan Dealmark Pvt Ltd.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Roshan Dealmark Pvt Ltd.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Roshan Dealmark Pvt Ltd.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has scheduled a Board Meeting on 04/09/2026 to consider and approve various resolutions, including the re-appointment of an Independent Director, related party transactions, and the 46th Annual General Meeting.
Tavexia Lifecare Ltd
Tavexia Lifecare Ltd has expanded into the pharmaceutical business as a new growth vertical, strengthening its presence in the healthcare and lifecare ecosystem. The company plans to explore opportunities across the pharmaceutical value chain, including pharmaceutical products, APIs, intermediates, specialty chemicals, nutraceuticals, and related manufacturing opportunities.
Sattva Sukun Lifecare Ltd
Sattva Sukun Lifecare Ltd has changed its name to Tavexia Lifecare Ltd, with the Ministry of Corporate Affairs and BSE approving the change.
Sattva Sukun Lifecare Ltd
Sattva Sukun Lifecare Ltd publishes newspaper clipping of un-audited financial results for Q1 2026, as per SEBI (LODR) Regulation 2015.
Sattva Sukun Lifecare Ltd
Sattva Sukun Lifecare Ltd has announced its un-audited financial results for the first quarter ended June 30, 2026, with the Board of Directors approving the results and taking on record the Limited Review Report issued by Statutory Auditors M/s. SSRV & Associates, Chartered Accountants, Mumbai.